Printer Friendly

MEDIA BRIEFING: NEUROSCIENTIST DISCOVERS MOLECULAR MECHANISMS OF COCAINE ADDICTION AND SCHIZOPHRENIA

 MEDIA BRIEFING: NEUROSCIENTIST DISCOVERS MOLECULAR MECHANISMS
 OF COCAINE ADDICTION AND SCHIZOPHRENIA
 Area of Brain Activated by Cocaine Craving Located
 WHO: Hans C. Fibiger, Ph.D., professor and head, Division of
 Neurological Sciences, Department of Psychiatry, the
 University of British Columbia, will discuss his
 identification of biomedical mechanisms that underlie both
 drug addiction and the actions of drugs for schizophrenia.
 Fibiger has discovered a way to visualize individual nerve
 cells that are affected by drugs of abuse, such as
 cocaine, and drugs that are used in the treatment of
 schizophrenia. He has also identified the area of the
 brain that is activated to create the intense craving for
 cocaine experienced by recovering addicts.
 Fibiger is the principal investigator of a $500,000
 Bristol-Myers Squibb Unrestricted Neuroscience Research
 Grant given to the University of British Columbia. This
 no-strings-attached funding will assist the university in
 advancing its research programs in the biochemistry of the
 brain over the next five years. To date, Bristol-Myers
 Squibb has given $5.3 million in unrestricted research
 grants to 11 leading neuroscience research centers.
 WHAT: Telephone Media Briefing
 WHEN: Thursday, July 23
 1-1:45 p.m. EDT
 HOW: To join teleconference call:
 Dial 800-437-2797 in the United States
 Dial 212-478-3020 Internationally or from Canada
 When you hear "Please enter your conference code," enter
 102805
 CONTACT: For U.S. media contact: Paula Jennings of Ketchum Public Relations, 202-835-8842, for Bristol-Myers Squibb Company, or Elizabeth M. Sigler of Bristol-Myers Squibb Company, 212-546-5764. For Canadian media contact: Connie Filletti of the University of British Columbia, 604-822-2644.
 -0- 7/22/92


CO: Bristol-Myers Squibb Company; University of British Columbia ST: IN: MTC SU:

KD -- DC003 -- 1692 07/22/92 08:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1992
Words:280
Previous Article:FMPI PROJECTS PROFIT FOR FIRST QUARTER ENDING AUG. 30, 1992
Next Article:BLACK & DECKER REPORTS SALES AND EARNINGS GAINS IN SECOND QUARTER; DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
CoCensys' Ganaxolone Effective Against Cocaine-Induced Seizures In Preclinical Study
The promise of strung-out flies.
NIH Research Shows Response to Cocaine Linked to Biological Clock Genes.
$4.6 Million in 'Freedom to Discover' Grants Awarded To 10 Leading Medical Research Institutions; Bristol-Myers Squibb Provides 'No-Strings-Attached'...
The cell biology of addiction.
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters